RMTI — Rockwell Medical Income Statement
0.000.00%
Last trade - 00:00
- $58.21m
- $59.80m
- $83.61m
- 13
- 53
- 60
- 37
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 61.3 | 62.2 | 61.9 | 72.8 | 83.6 |
Cost of Revenue | |||||
Gross Profit | 2.84 | 2.73 | -2.42 | 4.08 | 8.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 95.8 | 90.6 | 92.3 | 89.6 | 90.3 |
Operating Profit | -34.5 | -28.4 | -30.3 | -16.8 | -6.67 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -34.1 | -30.9 | -32.7 | -18.7 | -8.44 |
Net Income After Taxes | -34.1 | -30.9 | -32.7 | -18.7 | -8.44 |
Net Income Before Extraordinary Items | |||||
Net Income | -34.1 | -30.9 | -32.7 | -18.7 | -8.44 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -34.1 | -30.9 | -32.7 | -18.7 | -8.44 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -6.08 | -4.49 | -3.83 | -1.89 | -0.362 |